Will end 2012 with higher sales, profits: Ranbaxy

Ranbaxy MD and CEO Arun Sawhney told CNBC-TV18 that the pharmaceutical company would end fiscal 2012 with better sales and profits. "In sales and profitability, we will post a performance better than last year. However, challenges such as forex and credit risk, and regulations will not go away soon."

Meanwhile Tsutomu Une, chairman Ranbaxy and executive director of parent company Daiichi Sankyo put to rest rumours of plans to delist Ranbaxy from the Indian market. "We have no intention to delist Ranbaxy from the Indian market. It is the pride of India and must be listed here," Une said.

Also read: Ranbaxy launches malaria drug Synriam

To mark World Malaria Day on Wednesday, Ranbaxy launched a new malaria treatment drug Synriam in India and is working to introduce it in other Asian countries, Africa and South America. The drug is used to treat plasmodium falciparum malaria. Ranbaxy, majority owned by Japan's Daiichi Sankyo Co, received the Indian drug regulator's approval for the product in 2011.

Malaria is a major public health problem in more than 90 countries that host about 40% of the global population. The deadly disease is estimated to cause up to 250 million new infections worldwide every year.

Also watch the accompanying video.